Author

Jason Jisheng Wu

Observed name: J. Wu

Institution: Suzhou Zelgen Biopharmaceuticals Co., Ltd. (China)

Observed institutions: First Affiliated Hospital of Xiamen University, Suzhou Zelgen Biopharmaceuticals Co., Ltd. (China)

ORCID: 0009-0004-1583-4240

Observed ORCID: 0009-0004-1583-4240

OpenAlex ID: A5039707262

Updated results of the phase 1 dose escalation and expansion study of alveltamig (ZG006), a trispecific T cell engager targeting DLL3/DLL3/CD3, as monotherapy in patients with refractory small cell lung cancer or neuroendocrine carcinoma.

2026 · Qiming Wang, Jianhua Shi, et al. · Journal of Clinical Oncology · 1

EP08.01-071 Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Non-Squamous NSCLC

2022 · J. Zhao, J. Wu, et al. · Journal of Thoracic Oncology · 1

Preliminary results of ZG005, a bispecific antibody targeting PD-1 and TIGIT, in combination with chemotherapy with or without bevacizumab as first-line treatment for advanced cervical cancer.

2025 · Hanmei Lou, Shuxia Cheng, et al. · Journal of Clinical Oncology

Works count: 3

Citation count: 2

H-index: 1

I10-index: